BML-277 (Chk2 Inhibitor II) is a Chk2 (checkpoint kinase 2) inhibitor. BML-277 protects T cells from apoptosis by controlling the response of p53 to radiation-induced DNA breaks. This is suggestive of BML-277's use as an adjuvant for radiation therapy in cancer. BML-277 is 1000-fold more selective toward Chk2 serine/threonine kinase than for Chk1 and Cdk1/B kinases. It has also been found to weakly inhibit 31 other kinases.
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn